More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Kup ten ebook, a 1 kolejny otrzymasz GRATIS!
Język Angielski ● Format PDF ● Strony 584 ● ISBN 9781420037937 ● Wydawca CRC Press ● Opublikowany 2002 ● Do pobrania 3 czasy ● Waluta EUR ● ID 5697838 ● Ochrona przed kopiowaniem Adobe DRM
Wymaga czytnika ebooków obsługującego DRM